Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3629 Target Snapshot

Casein kinase II subunit alpha · SINGLE PROTEIN · Homo sapiens

2,617Compounds
666Assays
8Approved Drugs
2,691.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Casein kinase II subunit alpha shows clinical signal disease relevance led by COVID-19. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P68400. Start with COVID-19, then reuse UniProt P68400 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with COVID-19, then reuse UniProt P68400 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
COVID-19

Casein kinase II subunit alpha shows clinical signal disease relevance led by COVID-19. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with COVID-19 because it currently carries clinical signal support. Linked drugs include SILMITASERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Casein kinase II subunit alpha as ChEMBL target CHEMBL3629, mapped to UniProt P68400. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Casein kinase II subunit alpha
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3629
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P68400
Casein kinase II subunit alpha
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Casein kinase II subunit alpha is the right protein anchor across sources, using UniProt P68400 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why COVID-19 is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCasein kinase II subunit alpha
UniProt AccessionP68400
Component TypeProtein
Sequence Length391 aa

Casein kinase II subunit alpha

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Casein kinase II subunit alpha, mapped to UniProt P68400. Sequence length is 391 aa.

Mapped IDP68400
Review nameCasein kinase II subunit alpha
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Casein kinase II subunit alpha shows clinical signal disease relevance led by COVID-19. 4 more disease programs remain visible in the same review block.

Clinical signal Phase II
COVID-19
1 linked drug · 1 direct · 1 efficacy
Linked drugSILMITASERTIB
Clinical signal Phase I
basal cell carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugSILMITASERTIB
Clinical signal Phase I
cholangiocarcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugSILMITASERTIB
Clinical signal Phase I
medulloblastoma
1 linked drug · 1 direct · 1 efficacy
Linked drugSILMITASERTIB
Clinical signal Phase I
multiple myeloma
1 linked drug · 1 direct · 1 efficacy
Linked drugSILMITASERTIB
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with COVID-19 because it currently carries clinical signal support. Linked drugs include SILMITASERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseCOVID-19
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

8
Approved
6
Phase III
15
Phase II
7
Phase I
Assay Mix

Activity Type Distribution

IC501,620.0
KI869.0
EC502.0
KD200.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4089961 10.89 Kd 0.01288 Preclinical
CHEMBL4077554 10.5 Kd 0.03162 Preclinical
CHEMBL3103191 10.32 Kd 0.0482 Preclinical
CHEMBL4099729 10.03 Kd 0.09333 Preclinical
CHEMBL3699289 9.89 IC50 0.13 Preclinical
CHEMBL3699277 9.85 IC50 0.14 Preclinical
CHEMBL3699234 9.82 IC50 0.15 Preclinical
CHEMBL3699295 9.8 IC50 0.16 Preclinical
CHEMBL4075338 9.79 Kd 0.1622 Preclinical
CHEMBL3699235 9.77 IC50 0.17 Preclinical
Distribution

pChEMBL Value Distribution

152
5.0
275
5.5
324
6.0
333
6.5
172
7.0
151
7.5
129
8.0
58
8.5
32
9.0
47
9.5
pChEMBL
Approved Drugs

Approved Drugs

BELUMOSUDIL
CHEMBL2005186
Approved 2021
FEDRATINIB
CHEMBL1287853
Approved 2019
ABEMACICLIB
CHEMBL3301610
Approved 2017
MIDOSTAURIN
CHEMBL608533
Approved 2017
PALBOCICLIB
CHEMBL189963
Approved 2015
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

666
Total Assays
796
Tested Compounds
3
Assay Types
Binding — 520 assays, 796 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 386 545 7.0
assay format 62 151 6.1
cell-based format 62 100 6.8
subcellular format 10 0
Functional — 144 assays, 209 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 143 1 5.8
assay format 1 208 6.1
ADME — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0
cell-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine